ArticleCell death & disease2026
cGAS-STING/HMGB1-mediated senescence induced by LRRK2 accelerates cartilage degeneration in osteoarthritis.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- An ultrasound-responsive hydrogel with piezoelectric-enhanced bioelectric-vesicular coupling alleviates mitochondrial dysfunction and inflammation for osteoarthritis therapy.Bioactive materials · 2027Article
- Cellular senescence and the SASP in skeletal ageing: convergent mechanisms of progressive bone loss in osteoporosis.Biogerontology · 2026Review
- cGAS-STING signaling in aging and age-related diseases: therapeutic promise and precaution.Archives of pharmacal research · 2026Review
- Inflammaging and immunosenescence-driven remodeling of the immune microenvironment in osteoarthritis: mechanisms, immune regulation and immune reprogramming.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Mitochondrial dysfunction-driven senescence is a central mechanism in the development of osteoarthritis (OA). Leucine-rich repeat kinase 2 (LRRK2), a multifunctional kinase implicated in maintaining mitochondrial homeostasis, has been examined in several inflammatory conditions. However, its role in regulating cellular senescence and its pathogenic contribution to OA remain insufficiently understood. To clarify the mechanism by which LRRK2 contributes to OA, RNA-seq and bioinformatics analysis were performed, followed by in vivo validation using a destabilization of medial meniscus (DMM) rat model in which LRRK2 was overexpressed via recombinant adeno-associated virus (rAAV). Complementary in vitro experiments were carried out to assess the impact of LRRK2 on mitochondrial dysfunction and senescence in chondrocytes. Our posttranscriptional analyses identified regulated factor influencing OA-related gene expression and revealed a strong association between LRRK2 and senescence-related regulatory genes in OA. rAAV-mediated LRRK2 overexpression accelerated chondrocyte senescence and worsened cartilage degeneration in DMM-induced OA. LRRK2 promoted HMGB1 upregulation by modulating GTPase activity, aggravating chondrocyte senescence. LRRK2 activated the cGAS-STING signaling pathway, increasing HMGB1 expression, exacerbating cellular senescence, and intensifying mitochondrial dysfunction. Treatment with the STING inhibitor H-151 partially mitigated the LRRK2-induced enhancement of chondrocyte senescence and mitochondrial impairment. This study demonstrates that LRRK2 drives chondrocyte senescence in OA by activating the cGAS-STING-HMGB1 axis, highlighting LRRK2 as a potential therapeutic target for OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.